Santarus gains on Uceris approval, 2013 guidance

Santarus Inc. (NASDAQ:SNTS) gained $1.24 (11%) to $12.52 on Tuesday after FDA approved Uceris budesonide late Monday to induce remission of mild to moderate active ulcerative colitis (UC). The stock move translates to a gain in market cap of $78.1 million for a closing valuation of $788.7 million. Also on Monday, Santarus introduced 2013 guidance and said it expects total revenues for the year of $320-$325 million. The Street is expecting $301.3 million. ...